This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cho, H.-J. Articles by Yoon, Y.-s. Search for Related Content PubMed PubMed Citation Articles by Cho, H.-J. Articles by Yoon, Y.-s. Related Collections Related Article

(Circulation Research. 2006;98:990.)
© 2006 American Heart Association, Inc.

Editorials

Synergism of Hematopoietic Cytokines for Infarct Repair

Hyun-Jai Cho, Young-sup Yoon

From the Division of Cardiovascular Research, Caritas St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Mass.

Correspondence to Young-sup Yoon, MD, PhD, Division of Cardiovascular Research, Caritas St. Elizabeth’s Medical Center, 736 Cambridge St, Boston, MA 02135. E-mail young.yoon@tufts.edu

See related article, pages 1098–1105

Key Words: G-CSF • hematopoietic cytokine • myocardial regeneration • repair • myocardial infarction

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Over the past few years, the field of stem cell biology and its therapeutic application in cardiovascular diseases has expanded remarkably and moved to the forefront of cardiovascular science. Promising results from experimental studies with bone marrow (BM)-derived stem or progenitor cells^1–3 prompted initiation of clinical trials in ischemic heart diseases (IHD). Pilot clinical trials^4,5 demonstrated that cell therapy using various BM-derived cells are safe and effective for treating IHD. The discovery that BM includes various stem cells spawned the strategy of directly mobilizing and homing BM cells into the heart to regenerate injured tissue.⁶ This concept is appealing because invasive procedures related to harvesting and delivering BM cells into the heart can be avoided.

The strategy of mobilizing stem cells from BM was initially contrived by hematologists to accelerate recovery after cancer chemotherapy.⁷ A number of hematopoietic cytokines, including granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF), flt3 ligand (FL), and erythropoietin have been tested for mobilization and repopulation of the hematopoietic system. G-CSF is the most widely investigated hematopoietic growth factor in animals and patients. In addition to mobilizing BM cells, G-CSF induces proliferation, differentiation, and survival of hematopoietic cells. Recently, G-CSF was reported to have a direct action on nonhematopoietic cells expressing G-CSF receptors such as cardiomyocytes,⁸ endothelial cells,⁸ and neuronal cells. SCF was cloned as a ligand for c-kit.⁹ SCF exerts its activity at the early stages of hematopoiesis in BM and acts synergistically with CSFs. Flt3 is a . . . [Full Text of this Article]

Related Article:

Postinfarct Cytokine Therapy Regenerates Cardiac Tissue and Improves Left Ventricular Function

Buddhadeb Dawn, Yiru Guo, Arash Rezazadeh, Yiming Huang, Adam B. Stein, Greg Hunt, Sumit Tiwari, Jai Varma, Yan Gu, Sumanth D. Prabhu, Jan Kajstura, Piero Anversa, Suzanne T. Ildstad, and Roberto Bolli
Circ. Res. 2006 98: 1098-1105. [Abstract] [Full Text] [PDF]